Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides

Antisense and Nucleic Acid Drug Development

Volumn 6, Issue 1, 1996, Pages 9-16

  Liu, Xiangjun ^a   Pogo, Beatriz G T ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Box 1131 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RNA;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTO ONCOGENE;

EID: 0029886613     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1996.6.9     Document Type: Article

References (49)

1. AGRAWAL, S., TEMSAMANI, J., and TANG, J. Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7079-7083.
2. BACON, T., and WICKSTROM, E. (1991). Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficiency at the 5′ cap region. Oncogene Res. 6, 13-19.
3. BAYEVER, E., IVERSEN, P.L., BISHOP, M.R., SHARP, J.G., TEWARY, K., ARNESON, M.A., PIRRUCCELLO, S.J., RUDDON, R.W., KESSINGER, A., ZON, G., and ARMITAGE, G.O. (1993). Systematic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome. Antisense Res. Dev. 3, 383-390.
4. BENNETT, C.F., CHIANG, M.Y., CHAN, H., SHOEMAKER, J.E.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Molec. Pharmacol. 41, 1023-1033.
5. BERTRAM, J., KILLIAN, M., BRYSCH, W., SCHLINGENSIEPEN, K.-H., and KNEBA, M. (1994). Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem. Biophys. Res. Commun. 200, 661-667.
6. HER2 overexpressing tumors. In: Antigen and Antibody Engineering in Breast Cancer Diagnosis. R.L. Ceriani, ed. (Plenum Publishing Corp, New York), pp. 83-94.
7. COLIGE, A., SOKOLOV, B.P., NUGENT, P., BASERGA, R., and PROCKOP, D.J. (1993). Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry 32, 7-11.
8. COLOMER, R., LUPU, R., BACUS, S.S., and GELMANN, E.P. (1994). erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. J. Br. Cancer Res. 70, 819-825.
9. COUSSENS, L., YANG-FENG, T.L., LIAO, Y.-C., CHEN, E., GRAY, A., McGRATH, J., SEEBURG, P.H., LIBERMANN, T.A., SCHLESSINGER, J., FRANCKE, U., LEVINSON, A., and ULLRICH, A. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139.
10. DAAKA, Y., and WICKSTROM, E. (1992). Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T324-transformed NIH 3T3 cells. Oncogene Res. 5, 279-289.
11. DiFIORE, P.P., PIERCE, J.H., KRAUS, M.H., SEGATTO, O., KING, C.R., SCHLESSINGER, J., and AARONSON, S.A. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178-182.
12. FENDLY, B.M., WINGET, M., HUDZIAK, R.M., LIPARI, M.T., MAPIER, M.A., and ULLRICH, A. (1990). The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. Cancer Res. 50, 1550-1558.
13. HIGGINS, K.A., PEREZ, J.R., COLEMAN, T.A., DORSHKIND, K., McCOMAS, W.A., SARMIENTO, U.M., ROSEN, D.A., and NARAYANAN, R. (1993). Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90, 9901-9905.
14. HOLLYWOOD, D., and HURST, H.C. (1993). A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumor lines. EMBO J. 12, 2369-2375.
15. HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172.
16. HER-2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 84, 7159-7163.
17. HYNES, N.E., GERBER, H.A., SAURER, S., and GRONER, B. (1989). Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 39, 167-173.
18. IVERSEN, P. (1993). In vivo studies with phosphorothioate oligonucleotides: Rationale for systemic therapy. In: Antisense Research and Applications. S.T. Crooke, and B. Lebleu, eds. (Boca Raton, FL, CRC Press) pp. 461-469.
19. IVERSEN, P.L., MATA, J., TRACEWELL, W.G., and ZOU, G. (1994). Pharmacokinetics of an antisense phosphorothioate oligonucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4, 43-52.
20. KING, C.R., KASPRZYK, P.G., FISHER, P.H., BIRD, R.E., and TURNER, N.A. (1994). Abstract Int. Cancer Res. Symposium: New approaches in the Therapy of Breast Cancer. Georgetown University Medical Center, Washington, DC, October 20-21.
21. KITAJIMA, I., SHINOHARA, T., BILAKOVICS, J., BROWN, D.A., XU, X., and NERENBERG, M. (1992). Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 258, 1792-1795.
22. KRAUS, M.H., POPESCU, N.C., AMSBOUGH, S.C., and KING, C.R. (1987). Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6, 605-610.
23. HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255-263.
24. MULLER, W.J., SINN, E., PATTENGATE, P.K., WALLACE, R., and LEDER, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
25. PIER, G.N., NICORTRA, M.R., BIGOTTI, A., VENTURO, I., SLAMON, D.J., FENDLY, B.M., and ULLRICH, A. (1990). Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 45, 457-461.
26. PIERCE, J.H., ARSTEIN, P., DiMARCO, E., ARTRIP, J., KRAUS, M.H., LEONARDO, F., DiFIORE, P.P., and AARONSON, S.A. (1991). Oncogene potential of erbB-2 in human breast mammary epithelial cells. Oncogene 6, 1189-1194.
27. PRESS, M.F., CORDON-CARDO, C., and SLAMON, D. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5, 953-962.
28. PRESS, M.F., PIKE, M.C., CHAZIN, V.R., HUNG, G., UDOVE, J.A., MARKOWICZ, M., DANYLUK, J., GODOLPHIN, W., SLIWKOWSKI, M., AKITA, R., PATERSON, M.C., and SLAMON, D.J. (1993). Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53, 4960-4970.
29. RATAJCZAK, M.Z., KANT, J.A., LUGER, S.M., HIJIVA, N., ZHANG, J., ZON, G., and GEWIRTZ, A.M. (1992). In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 89, 11823-11827.
30. RESNICOFF, M., SELL, C., RUBINI, M., COPPOLA, D., AMBROSE, D., BASERGA, R., and RUBIN, R. (1994). Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IHF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54, 2218-2222.
31. SAKAKURA, C., HAGIWARA, A., TSUJIMOTO, H., OZAKI, K., SAKAKIBARA, T., OYAMA, T., OGAKI, T., OGAKI, M., and TAKAHASHI, T. (1994). Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen. Br. J. Cancer 70, 1060-1066.
32. SARMIENTO, U.M., PEREZ, J.R., BECKER, J.M., and NARAYANAN, R. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4, 99-107.
33. SHEPARD, H.M., LEWIS, G.D., SARUP, J.C., FENDLY, B.M., MANEVAL, D., MORDENTI, J., FIGARI, I., KOTTS, C.E., PALLADINO, M.A., ULLRICH, A., and SLAMON, D. (1991). Monoclonal antibody therapy of human cancer: Taking the HER2 proto-oncogene to the clinic. J. Clin. Immunol. 11, 117-127.
34. SIMONS, M., EDELMAN, E.R., DeKEYSER, J.L., LANGER, R., and ROSENBERG, R.D. (1992). Antisense c-myc oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
35. SKORSKI, T., SKORSKA, M.N., NICOLAIDES, N.C., SZCZYLIK, C., IVERSEN, P., IOZZO, R.V., ZON, G., and CALABRETTA, B. (1994). Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 4504-4508.
36. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A., and McGUIRE, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
37. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.J., UDOVE, J., ULLRICH, A., and PRESS, M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
38. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 261, 1004-1012.
39. STEIN, C.A., and KRIEG, A.M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligonucleotides. Antisense Res. Dev. 4, 67-69.
40. TROJAN, J., BLOSSEY, V.B.K., JOHNSON, T.R., RUDIN, S.D., TYROCINSKI, M., and ILAN, J. (1992). Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 89, 4874-4878.
41. TROJAN, J., JOHNSON, T.R., RUDIN, S.D., ILAN, J., TYROCINSKI, M., and ILAN, J. (1993). Treatment and prevention of rat glioblastoma by immunologic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259, 94-96.
42. VAN DE VIJVER, M.J., PETERSE, J.L., MOOI, W.J., WISMAN, P., LOMANS, J., DALESIO, O., and NUSSE, R. (1988). Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 319, 1239-1245.
43. VAN DE VIJVER, M.J., VAN DER BERSSELAAR, R., DeVILEE, P., CORNELISSE, C., PETERSE, J., and NUSSE, R. (1987). Amplification of the neu-(c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell Biol. 7, 2019-2023.
44. VARLEY, J.M., SWALLOW, J.E., BRAMMER, W.J., WHITTAKER, J.L., and WALKER, R.A. (1987). Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1, 423-430.
45. VENTER, D.J., TSUI, N.L., KUMAR, S., and GULLICK, W.J. (1987). Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet 2, 69-72.
46. WAGNER, R.W., MATTEUCCI, M.D., LEWIS, J.G., GUTIERREZ, A.J., MOULDS, C., and FROEHLER, B.C. (1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510-1513.
47. YAMAMOTO, T., IKAWA, S., AKIYAMA, T., SEMBA, K., NOMURA, N., MIYAJIMA, N., SAITO, T., and TOYOSHIMA, K. (1986). Similarity of protein encoded by the human erbB-2 gene to epidermal growth factor receptor. Nature 319, 230-234.
48. YASWEN, P., STEMPFER, M., and GHOSH, K. (1992). Effects of sequence of thiolated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 3, 67-77.
49. YU, D.H., WANG, S.S., DULSKI, K.M., TSAI, C.M., NICOLSON, G.L., and HUANG, M.C. (1994). c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 54, 3260-3266.